De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Maravai LifeSciences Holdings Beheer
Beheer criteriumcontroles 4/4
De CEO Maravai LifeSciences Holdings' is Trey Martin, benoemd in Jul2023, heeft een ambtstermijn van 1.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.30M, bestaande uit 32.6% salaris en 67.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.15% van de aandelen van het bedrijf, ter waarde $ 3.15M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 3.9 jaar.
Belangrijke informatie
Trey Martin
Algemeen directeur
US$2.3m
Totale compensatie
| Percentage CEO-salaris | 32.6% |
| Dienstverband CEO | 1.3yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 2.3yrs |
| Gemiddelde ambtstermijn bestuur | 3.9yrs |
Recente managementupdates
Recent updates
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Jul 18
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Jul 12RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$132m |
| Mar 31 2024 | n/a | n/a | -US$131m |
| Dec 31 2023 | US$2m | US$750k | -US$119m |
| Sep 30 2023 | n/a | n/a | US$25m |
| Jun 30 2023 | n/a | n/a | US$75m |
| Mar 31 2023 | n/a | n/a | US$153m |
| Dec 31 2022 | US$15m | US$660k | US$220m |
Compensatie versus markt: De totale vergoeding ($USD 2.30M ) Trey } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van Trey is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Trey Martin (49 yo)
1.3yrs
Tenure
US$2,301,864
Compensatie
Mr. William E. Martin, III, also known as Trey, is Director of Maravai LifeSciences Holdings, Inc. from July 31, 2024. He was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. si...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.9yrs | US$5.22m | 0.21% $ 4.2m | |
| CEO & Director | 1.3yrs | US$2.30m | 0.15% $ 3.0m | |
| Executive VP & CFO | 7.4yrs | US$2.79m | 0.021% $ 415.9k | |
| Executive VP & Chief Administrative Officer | 2.3yrs | US$2.83m | 0.040% $ 787.3k | |
| Executive VP & GM of Cygnus Technologies | 7yrs | US$2.26m | 0.018% $ 366.0k | |
| President of Nucleic Acid Production | 1.6yrs | US$2.99m | 0.023% $ 449.4k | |
| Senior Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP | 3.9yrs | US$701.40k | 0.018% $ 359.6k | |
| Executive VP & Chief Commercial Officer | 1.7yrs | geen gegevens | 0.014% $ 276.6k | |
| Chief Innovation Officer | 1.7yrs | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MRVI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.9yrs | US$5.22m | 0.21% $ 4.2m | |
| CEO & Director | less than a year | US$2.30m | 0.15% $ 3.0m | |
| Independent Director | 1.3yrs | US$435.03k | geen gegevens | |
| Non-Independent Director | 3.9yrs | US$370.48k | 0.0030% $ 60.1k | |
| Non-Independent Director | 3.9yrs | US$367.98k | 0.0030% $ 60.1k | |
| Independent Director | 3.9yrs | US$360.48k | 0.022% $ 437.6k | |
| Independent Director | 3.9yrs | US$395.48k | 0.026% $ 507.9k | |
| Non-Independent Director | 3.9yrs | US$360.48k | 0.0030% $ 60.1k | |
| Non-Independent Director | 3.9yrs | US$360.48k | 0.0030% $ 60.1k | |
| Independent Director | 3.9yrs | US$367.98k | 0.015% $ 292.8k | |
| Independent Director | 3.9yrs | US$387.98k | 0.047% $ 929.6k |
3.9yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MRVI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).